Nuvation Bio (NYSE:NUVB) Earns “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of Nuvation Bio (NYSE:NUVB) in a research note released on Thursday morning,RTT News reports. They currently have a $5.00 target price on the stock. Wedbush also issued estimates for Nuvation Bio’s Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.05) EPS.

A number of other research firms also recently issued reports on NUVB. HC Wainwright cut their target price on shares of Nuvation Bio from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Jones Trading started coverage on shares of Nuvation Bio in a research report on Wednesday, March 12th. They issued a “buy” rating and a $10.00 price target on the stock. JMP Securities started coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They set a “market outperform” rating and a $6.00 target price for the company. Citizens Jmp started coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They set a “mkt outperform” rating and a $6.00 target price for the company. Finally, Citigroup started coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They set an “outperform” rating for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $7.83.

Nuvation Bio Stock Performance

NUVB opened at $2.24 on Thursday. The firm’s 50-day simple moving average is $2.01 and its 200-day simple moving average is $2.36. The firm has a market cap of $758.64 million, a price-to-earnings ratio of -1.03 and a beta of 1.42. Nuvation Bio has a twelve month low of $1.54 and a twelve month high of $3.97.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The company had revenue of $3.08 million for the quarter, compared to analyst estimates of $0.42 million. As a group, sell-side analysts anticipate that Nuvation Bio will post -0.36 EPS for the current fiscal year.

Insider Transactions at Nuvation Bio

In other news, insider Dongfang Liu sold 20,000 shares of the stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $2.50, for a total value of $50,000.00. Following the completion of the sale, the insider now owns 12,000 shares of the company’s stock, valued at approximately $30,000. This represents a 62.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David Hung acquired 200,000 shares of the business’s stock in a transaction dated Friday, April 4th. The stock was bought at an average cost of $1.66 per share, with a total value of $332,000.00. Following the acquisition, the chief executive officer now owns 58,481,054 shares in the company, valued at $97,078,549.64. The trade was a 0.34% increase in their position. The disclosure for this purchase can be found here. Company insiders own 29.93% of the company’s stock.

Institutional Investors Weigh In On Nuvation Bio

Large investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Nuvation Bio in the 4th quarter valued at approximately $27,000. Forum Financial Management LP acquired a new stake in shares of Nuvation Bio in the 4th quarter valued at approximately $29,000. Cerity Partners LLC acquired a new stake in Nuvation Bio during the 4th quarter valued at $31,000. Firethorn Wealth Partners LLC bought a new position in Nuvation Bio during the first quarter worth $35,000. Finally, Russell Investments Group Ltd. boosted its position in Nuvation Bio by 15,183.7% during the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock worth $42,000 after purchasing an additional 15,791 shares during the period. Institutional investors and hedge funds own 61.67% of the company’s stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.